A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life

PharmacoEconomics

Volumn 11, Issue SUPPL. 1, 1997, Pages 24-34

  Dahlof C ^a   Bouchard, J ^b   Cortelli, P ^c   Heywood, J ^d   Jansen, J P ^e   Pham, S ^f   Hirsch, J ^g   Adams, J ^h   Miller, D W ^h   Price, Kim L ^h  

^a Gothenburg Migraine Clinic   (Sweden)

^b St Josephs Hospital   (Canada)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e Schmerz Zentrum Berlin GmbH   (Germany)

^f GLAXOSMITHKLINE   (United States)

^g Hirsch Reid Consulting   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIOECONOMICS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; WELLBEING;

EID: 8544234245     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199700111-00005     Document Type: Article

References (21)

1. Dahlöf C. Assessment of health-related quality of life in migraine. Cephalalgia 1993; 13: 233-7
2. Kongpatanakul S, Strom BL. Quality of life, health status, and clinical drug research. PharmacoEconomics 1992; 2: 8-14
3. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
4. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-5
5. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991; 31: 300-5
6. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-13
7. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36: 137-43
8. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28: 171-7
9. Heywood J, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. I: design, methods and clinical findings. PharmacoEconomics 1997; 11 Suppl. 1: 11-23
10. Cortelli P, Dahlöf C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: workplace productivity and nonworkplace activity. PharmacoEconomics 1997; 11 Suppl. 1: 35-42
11. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: patient satisfaction. PharmacoEconomics 1997; 11 Suppl. 1: 43-50
12. Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1-96
13. Ware Jr JE. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center Hospitals, Inc., 1993
14. Ware Jr JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
15. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease-specific instrument to measure quality of life effects attributable to migraine. Poster presentation at the Health Services Research Association 10th Annual Meeting: 1993 June 27-29: Washington, DC
16. Reese PR, Joseph AJ. Quality translations - no substitute for psychometric evaluation [poster]. 2nd Meeting of the International Society for Quality of Life Research: 1995 Oct 14-17; Montreal
17. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995; 35: 449-54
18. Solomon GD, Nielsen K, Miller W. The effects of sumatriptan on migraine: health-related quality of life. Med Interface (June); 134-41
19. Dahlof C, Edwards C, Toth L. Sumatriptan injection is superior to placebo in the acute treatment of migraine - with regard to both efficacy and general well-being. Cephalalgia 1992; 12: 214-20
20. De Lissovoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994; 44 Suppl. 4: S56-62
21. Lipton TB, Stewart WF. Health-related quality of life in headache research. Headache 1995; 35: 447-8